title: Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects.
abstract: Topiramate is currently used in the treatment of epilepsy, but this anticonvulsant drug has also been reported to exert mood-stabilizing effects and induce weight loss in patients. Neuropeptide Y (NPY) is abundantly and widely distributed in the mammalian central nervous system and centrally administered NPY markedly reduces pharmacologically induced seizures and induces antidepressant-like activity as well as feeding behavior. Two other peptides, galanin and corticotropin-releasing hormone (CRH), have also been proposed to play a modulatory role in mood, appetite, and seizure regulation. Consequently, we investigated the effects of single and repeated topiramate (10 days, once daily: 40 mg/kg i.p.) or vehicle treatment in 'depressed' flinders sensitive line (FSL) and control Flinders resistant line (FRL) rats on brain regional peptide concentrations of NPY, galanin, and CRH. The handling associated with repeated injections reduced hippocampal levels of NPY- and galanin-like immunoreactivities (LI) while NPY- and CRH-LI levels were increased in the hypothalamus, regardless of strain or treatment. In the hippocampus, concentrations of NPY-LI, galanin-LI, and CRH-LI were lower in FSL than FRL animals. Repeated topiramate treatment selectively normalized NPY-LI in this region in the FSL animals. In the hypothalamus, galanin-LI was reduced in FSL compared to FRL animals. Topiramate elevated the hypothalamic concentrations of NPY-LI, CRH-LI, and galanin-LI in both strains. Furthermore, topiramate elevated serum leptin but not corticosterone levels. The present findings show that topiramate has distinct effects on abnormal hippocampal levels of NPY, with possible implications for its anticonvulsant and mood-stabilizing effects. Furthermore, stimulating hypothalamic NPY-LI, CRH-LI and galanin-LI as well as serum leptin levels may be associated with the weight loss-inducing effects of topiramate.
authors.affiliation: Department of Physiology and Pharmacology, Division of Pharmacology, Institution of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Henriette
authors.initials: H
authors.lastname: Husum
authors.forename: Daniel
authors.initials: D
authors.lastname: Van Kammen
authors.forename: Evelien
authors.initials: E
authors.lastname: Termeer
authors.forename: G
authors.initials: G
authors.lastname: Bolwig
authors.forename: A
authors.initials: A
authors.lastname: Mathé
mesh_terms: D000339:Affect / Q000187:drug effects; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism*; D003863:Depression / Q000188:drug therapy / Q000378:metabolism; D004195:Disease Models, Animal; D004334:Drug Administration Schedule / Q000662:veterinary; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D019004:Galanin / Q000378:metabolism*; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism; D007031:Hypothalamus / Q000187:drug effects* / Q000378:metabolism; D020738:Leptin / Q000097:blood; D008297:Male; D009478:Neuropeptide Y / Q000378:metabolism*; D009778:Occipital Lobe / Q000187:drug effects / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013045:Species Specificity; D000077236:Topiramate; D015431:Weight Loss / Q000187:drug effects
chemical_list: D000927:Anticonvulsants; D020738:Leptin; D009478:Neuropeptide Y; D000077236:Topiramate; D005632:Fructose; D019004:Galanin; D003346:Corticotropin-Releasing Hormone; D003345:Corticosterone